Science & Enterprise subscription

Please share Science & Enterprise

RSS
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Antibody Combination Shown to Suppress HIV

T-cell infected by HIV

Results from a small-scale clinical trial show a combination of antibodies can suppress the HIV virus for many weeks after stopping antiretroviral therapy. . . . → Read More: Antibody Combination Shown to Suppress HIV

Technique Assessed for Comparing Effectiveness Between Drugs

Analytics

An academic-industry research team validated a statistical technique to evaluate the effectiveness of different drugs treating the same disease, without conducting separate head-to-head clinical trials. . . . → Read More: Technique Assessed for Comparing Effectiveness Between Drugs

HIV Drugs Formulated Into Once-Weekly Capsules

Medical and engineering researchers developed and tested in pigs a technique for packing several drugs into a capsule taken once a week to prevent and treat HIV infections. . . . → Read More: HIV Drugs Formulated Into Once-Weekly Capsules

Start-Up Lands $10M for Gene-Editing HIV Treatments

A new enterprise developing treatments using gene editing to eliminate HIV infections received $10 million in its seed funding round. . . . → Read More: Start-Up Lands $10M for Gene-Editing HIV Treatments

Gene Editing Could Lead to an HIV Cure

Researchers at Temple University and the University of Pittsburgh published a study, which involved gene editing to remove HIV DNA from rat and mouse models. . . . → Read More: Gene Editing Could Lead to an HIV Cure

Messenger RNA Engineered to Produce Antibodies

Academic and industry researchers demonstrated production of therapeutic antibodies inside cells of lab mice, offering a simpler and lower-cost alternative to monoclonal antibodies. . . . → Read More: Messenger RNA Engineered to Produce Antibodies

Biotech, Univ of Miami Spin-Off Vaccine Company

Biotechnology company Heat Biologics Inc. is licensing research from University of Miami in Florida to develop vaccines against infectious diseases, starting with the Zika virus, in a new subsidiary. . . . → Read More: Biotech, Univ of Miami Spin-Off Vaccine Company

Refillable HIV Prevention Implant in Development

A device implanted under the skin providing 60 days of antiretroviral drugs to prevent HIV infection is in development at Houston Methodist Research Institute. . . . → Read More: Refillable HIV Prevention Implant in Development

Start-Up Licenses Genetics Technology for HIV Diagnostics

David Raiser, left, and Iain MacLeod, founders of Aldatu Biosciences (Aldatu Biosciences)

19 May 2016. A spin-off company from Harvard University is licensing genetics research to develop more powerful tools to detect drug-resistant strains of HIV. Financial details of the agreement between the 2 year-old Aldatu Biosciences Inc. and Harvard were not disclosed.

Aldatu . . . → Read More: Start-Up Licenses Genetics Technology for HIV Diagnostics

Gates Funding RNA Treatment for HIV Infection

RNA molecule illustration (Nicolle Rager Fuller, National Science Foundation)

12 January 2016. The Bill and Melinda Gates Foundation is backing a biotechnology company’s early development of antibodies to treat human immunodeficiency virus or HIV based on RNA, nucleic acids expressed by a person’s genetic code. The foundation is supporting the work of Moderna Therapeutics, . . . → Read More: Gates Funding RNA Treatment for HIV Infection